Company Encyclopedia
View More
name
THDB
600867.SH
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug treatment, blood glucose monitoring, and patient education.
3.157 T
600867.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking17/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE18.09%A
    • Profit Margin44.72%A
    • Gross Margin72.63%A
  • Growth ScoreB
    • Revenue YoY12.74%B
    • Net Profit YoY259.17%A
    • Total Assets YoY14.45%A
    • Net Assets YoY11.00%B
  • Cash ScoreC
    • Cash Flow Margin223.63%C
    • OCF YoY12.74%B
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreA
    • Gearing Ratio12.46%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    THDB: The winter insulin injection has obtained an overseas drug registration certificate

    THDB recently obtained the product registration certificate for insulin aspart injection issued by the Indonesian Food and Drug Authority, with registration number DKI2570600143A1. This medication is a rapid-acting insulin primarily used to control postprandial blood sugar levels. The acquisition of this registration certificate will help THDB expand its international market, enhance its brand image, and strengthen its competitiveness in emerging markets

    Zhitong·
    SH
    600867
    +0.57%
    Zhitong·
    SH
    600867
    +0.57%

    THDB: Announced the shareholding status of the top ten shareholders and the top ten unrestricted shareholders before the share repurchase

    On October 17, 2025, Tonghua Dongbao held a board meeting to review and approve the share repurchase plan, and announced the situation of the top ten shareholders and the top ten unrestricted shareholders on the trading day prior to the share repurchase resolution. Dongbao Industrial Group Co., Ltd. holds 613,823,496 shares, accounting for 31.34%; Tianjin Zhenyi Equity Investment Partnership holds 183,058,967 shares, accounting for 9.35%. All shares are unrestricted circulating shares, and the top 10 shareholders are consistent with the top 10 unrestricted shareholders

    Zhitong·
    SH
    600867
    +0.57%
    Zhitong·
    SH
    600867
    +0.57%

    THDB plans to repurchase company shares for between 20 million and 40 million yuan

    According to the Zhitong Finance APP, Tonghua Dongbao announced that the company has decided to use its own funds to repurchase company shares for the employee stock ownership plan and/or equity incentive. The amount for this share repurchase will not be less than RMB 20 million (inclusive) and not more than RMB 40 million (inclusive), with the repurchase price not exceeding RMB 10 per share (inclusive)

    Zhitong·
    SH
    600867
    +0.57%
    Zhitong·
    SH
    600867
    +0.57%

    THDB: Insulin Glargine Injection has obtained overseas listing approval

    According to the Zhitong Finance APP, THDB announced that the company recently received the marketing authorization for its product Insulin Glargine Injection issued by the Ministry of Health of the Republic of the Union of Myanmar. Insulin Glargine is a long-acting insulin analog product that is injected once daily, with an effect duration of up to 24 hours after injection, providing a peakless blood concentration and steadily lowering the patient's blood sugar levels

    Zhitong·
    SH
    600867
    +0.57%
    Zhitong·
    SH
    600867
    +0.57%

    THDB: The domestic insulin market will continue to develop steadily in the next three years

    On October 9th, THDB held a performance briefing for the first half of 2025, stating that the domestic insulin market will continue to develop steadily over the next three years. The company is continuously developing new products, such as ultra-fast-acting insulin, degludec insulin liraglutide injection, and GLP-1/GIP dual-target receptor agonists, as well as expanding into new therapeutic areas, such as weight loss and gout, to continuously explore new market space and promote the company's long-term high-quality development

    Zhitong·
    SH
    600867
    +0.57%
    Zhitong·
    SH
    600867
    +0.57%
    © 2025 Longbridge｜Disclaimer